Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Chia Tai Tianqing Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Fosaprepitant dimeglumine
Fosaprepitant dimeglumine
2021-03-03
—
Fulvestrant
Fulvestrant
2020-02-07
2034
Breast neoplasms
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fulvestrant
neoplasms
,
breast neoplasms
,
triple negative breast neoplasms
Eribulin
breast neoplasms
,
neoplasms
Eribulin mesylate
breast neoplasms
,
neoplasms
Mycophenolate sodium
renal insufficiency
,
graft rejection
,
kidney transplantation
,
immunosuppression therapy
Docusate
sickle cell anemia
,
hematologic neoplasms
,
non-small-cell lung carcinoma
,
lung neoplasms
,
adenocarcinoma
,
squamous cell carcinoma
,
squamous cell neoplasms
,
migraine disorders
,
prostatic neoplasms
,
carcinoma
,
breast neoplasms
,
ovarian neoplasms
,
pancreatic neoplasms
,
sarcoma
,
ovarian epithelial carcinoma
,
schizophrenia
,
psychotic disorders
Benzimidazole
prostatic neoplasms
Sintilimab
non-small-cell lung carcinoma
,
lung neoplasms
Penpulimab
neoplasms
,
lung neoplasms
,
non-small-cell lung carcinoma
,
gastrointestinal neoplasms
,
colorectal neoplasms
,
pancreatic neoplasms
,
nasopharyngeal neoplasms
,
urologic neoplasms
,
digestive system neoplasms
,
gastrointestinal stromal tumors
,
neuroendocrine tumors
,
thyroid neoplasms
,
small cell lung carcinoma
,
glioblastoma
,
stomach neoplasms
,
gastrointestinal diseases
,
digestive system diseases
,
nasopharyngeal carcinoma
,
rectal neoplasms
,
lymphoma
,
squamous cell carcinoma of head and neck
,
squamous cell carcinoma
,
squamous cell neoplasms
,
esophageal squamous cell carcinoma
,
sarcoma
,
melanoma
,
pheochromocytoma
,
carcinoma
,
hepatocellular carcinoma
,
liver neoplasms
Lanifibranor
pharmacokinetics
Gilvetmab
second primary neoplasms
,
colonic neoplasms
,
rectal neoplasms
,
head and neck neoplasms
,
lymphoma
,
hodgkin disease
,
non-small-cell lung carcinoma
,
liver neoplasms
,
stomach neoplasms
,
hepatocellular carcinoma
,
squamous cell carcinoma of head and neck
,
squamous cell carcinoma
,
colorectal neoplasms
,
carcinoma
,
lung neoplasms
,
melanoma
,
adenocarcinoma
,
renal cell carcinoma
,
sarcoma
,
urologic neoplasms
,
transitional cell carcinoma
,
biliary tract neoplasms
,
esophageal neoplasms
,
esophageal squamous cell carcinoma
,
cholangiocarcinoma
,
pancreatic ductal carcinoma
,
pancreatic neoplasms
,
leiomyosarcoma
,
ovarian neoplasms
,
tertiary lymphoid structures
,
brain neoplasms
,
triple negative breast neoplasms
,
merkel cell carcinoma
,
neoplasm metastasis
,
breast neoplasms
,
neoplasms
,
endometrial neoplasms
,
uterine neoplasms
Enoblituzumab
sarcoma
,
leiomyosarcoma
,
liposarcoma
Efbemalenograstim alfa
non-small-cell lung carcinoma
,
lung neoplasms
,
febrile neutropenia
,
colorectal neoplasms
,
pancreatic neoplasms
,
ovarian neoplasms
,
uterine cervical neoplasms
,
neutropenia
,
breast neoplasms
,
neoplasms
Aglatimagene besadenovec
prostatic neoplasms
,
castration-resistant prostatic neoplasms
,
breast neoplasms
,
ovarian neoplasms
Spartalizumab
prostatic neoplasms
,
colorectal neoplasms
,
ovarian neoplasms
,
non-small-cell lung carcinoma
,
endometrial neoplasms
,
hemangiosarcoma
,
neoplasms
,
uterine cervical neoplasms
Lenograstim
breast neoplasms
,
prostatic neoplasms
,
neuroendocrine carcinoma
,
hodgkin disease
,
lymphoma
,
hiv infections
,
acquired immunodeficiency syndrome
,
progressive multifocal leukoencephalopathy
1
2
3
4
5
6
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use